These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31585951)

  • 1. Identification of a tumor-specific allo-HLA-restricted γδTCR.
    Kierkels GJJ; Scheper W; Meringa AD; Johanna I; Beringer DX; Janssen A; Schiffler M; Aarts-Riemens T; Kramer L; Straetemans T; Heijhuurs S; Leusen JHW; San José E; Fuchs K; Griffioen M; Falkenburg JH; Bongiovanni L; de Bruin A; Vargas-Diaz D; Altelaar M; Heck AJR; Shultz LD; Ishikawa F; Nishimura MI; Sebestyén Z; Kuball J
    Blood Adv; 2019 Oct; 3(19):2870-2882. PubMed ID: 31585951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control.
    Johanna I; Hernández-López P; Heijhuurs S; Scheper W; Bongiovanni L; de Bruin A; Beringer DX; Oostvogels R; Straetemans T; Sebestyen Z; Kuball J
    Front Immunol; 2021; 12():752699. PubMed ID: 34759930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.
    Johanna I; Hernández-López P; Heijhuurs S; Bongiovanni L; de Bruin A; Beringer D; van Dooremalen S; Shultz LD; Ishikawa F; Sebestyen Z; Straetemans T; Kuball J
    J Leukoc Biol; 2020 Jun; 107(6):1069-1079. PubMed ID: 32022317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The avidity of cross-reactive virus-specific T cells for their viral and allogeneic epitopes is variable and depends on epitope expression.
    van den Heuvel H; Heutinck KM; van der Meer-Prins EMW; Franke-van Dijk MEI; van Miert PPMC; Zhang X; Ten Berge IJM; Claas FHJ
    Hum Immunol; 2018 Jan; 79(1):39-50. PubMed ID: 29100943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
    Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
    Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
    Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
    Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
    Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
    Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual Placement of an EBV Epitope into the Groove of the Ankylosing Spondylitis-Associated HLA-B27 Allele Allows CD8+ T Cell Activation.
    Tedeschi V; Alba J; Paladini F; Paroli M; Cauli A; Mathieu A; Sorrentino R; D'Abramo M; Fiorillo MT
    Cells; 2019 Jun; 8(6):. PubMed ID: 31212633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
    Poncette L; Chen X; Lorenz FK; Blankenstein T
    J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
    Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
    Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cells are necessary for recognition of allelic, but not locus-mismatched or xeno-, HLA class I transplantation antigens.
    Borenstein SH; Graham J; Zhang XL; Chamberlain JW
    J Immunol; 2000 Sep; 165(5):2341-53. PubMed ID: 10946256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
    Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
    Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.
    Harris DT; Hager MV; Smith SN; Cai Q; Stone JD; Kruger P; Lever M; Dushek O; Schmitt TM; Greenberg PD; Kranz DM
    J Immunol; 2018 Feb; 200(3):1088-1100. PubMed ID: 29288199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.